An expert resource for medical professionals
Provided FREE as a service to women’s health

The Alliance for
Global Women’s Medicine
A worldwide fellowship of health professionals working together to
promote, advocate for and enhance the Welfare of Women everywhere

An Educational Platform for FIGO

The Global Library of Women’s Medicine
Clinical guidance and resourses

A vast range of expert online resources. A FREE and entirely CHARITABLE site to support women’s healthcare professionals

The Global Academy of Women’s Medicine
Teaching, research and Diplomates Association

This chapter should be cited as follows:
Policiano C, Clode N, et al, Glob. libr. women's med.,
ISSN: 1756-2228; DOI 10.3843/GLOWM.411393

The Continuous Textbook of Women’s Medicine SeriesObstetrics Module

Volume 5

Surveillance of fetal well-being

Volume Editor: Professor Diogo Ayres-de-Campos, University of Lisbon, Portugal


Sonographic Assessment of Fetal Growth

First published: February 2021

Study Assessment Option

By completing 4 multiple-choice questions (randomly selected) after studying this chapter readers can qualify for Continuing Professional Development awards from FIGO plus a Study Completion Certificate from GLOWM
See end of chapter for details


Fetal size and growth trajectories are important indicators of underlying fetal health. Growth anomalies have long been diagnosed after birth, by weighing the newborn and using terminologies such as low birth weight, macrosomia, small-for-gestational age (SGA) and large-for-gestational age (LGA).1 Both extremes of fetal growth are associated with adverse perinatal outcomes. Fetal growth-restriction (FGR) is the second most common finding associated with stillbirth,2,3 and undiagnosed late FGR constitutes a significant proportion of term stillbirths.4,5 Furthermore, undiagnosed FGR is associated with a higher risk of adverse neonatal outcomes (5-minute Apgar score <4, neonatal seizures, acidosis and neonatal death), when compared to FGR diagnosed during pregnancy.4,5

Fetal macrosomia is also associated with an increased risk of maternal complications such as arrested labor, instrumental vaginal delivery, cesarean delivery, postpartum hemorrhage, genital tract lacerations, as well as neonatal complications that include shoulder dystocia, birth trauma, fetal hypoxia and admission to the neonatal intensive care unit.6,7

For all these reasons, antenatal screening and diagnosis of fetal growth abnormalities is an important part of modern-day obstetrics. The most commonly used screening tool in low-risk populations is serial measurement of fundal height, the distance between the upper border of the pubic symphysis and the uterine fundus. This method has a low sensitivity for the diagnosis of FGR and macrosomia, but a high specificity for the latter, particularly when defined as birth weight above 4500 g.8,9,10 There is still much scientific uncertainty surrounding the benefit of third-trimester sonographic screening of FGR in low-risk pregnancies, as well as on the ideal time to perform it.11 Despite this, it is routinely used in many countries during the early third trimester, a strategy that has recently been endorsed by the World Health Organization (WHO).12


Whichever method is used for screening, fetal ultrasound has achieved a central role in modern-day diagnosis and management of fetal growth deviations. The most commonly used sonographic definition of SGA is an estimated fetal weight (EFW) below the 10th centile, and the definition of LGA is an EFW above the 90th centile for gestational age.13 The rationale behind using 10th and 90th centile cut-offs for weight-for-age distribution is similar to that of statistical inference using a p-value cut-off of 0.05 for rejecting the null hypothesis. It is also analogous to the concept of mean weight ± standard deviations as cut-offs for abnormal weight-for-age.1,14 Although 10% of normal fetuses will fall below the 10th centile (false positives), the probability that a fetus who is not achieving its growth potential (i.e. has growth restriction) is in this category is much higher, and the magnitude of probability is related to the severity of the disease process.1,15 An important feature underlying this concept is the establishment of growth charts using only “normal” fetuses. Another important understanding is that accurate knowledge of gestational age is essential for fetal growth assessment. For ultrasound dating of pregnancy, evidence is consistent in supporting the measurement of first-trimester crown–rump length (CRL) as the ideal method.16,17,18


A variety of sonographic parameters may be used to diagnose fetal growth abnormalities. Abdominal circumference is considered to be the most sensitive isolated parameter in prediction of SGA,19 especially in low-risk pregnancies and term fetuses, and has a good correlation with FGR and with morbidity parameters, such as hypoxia and acidemia.20,21 However, estimated fetal weight (EFW), using formulas that include head circumference, abdominal circumference, and femur length (FL) is considered the most accurate biometric parameter, in spite of a random error that can reach 14% (close to 400 g in an average term fetus). Errors appear to be higher for small and large fetuses.22

The majority of charts for sonographic EFW are designed to identify fetal growth abnormalities that occur during the third trimester.23,24 Second trimester fetal growth is usually assessed by longitudinal evaluations of the biparietal diameter.22


Accurate ultrasound and birth weight standards are essential for the detection of abnormal fetal growth, and the choice of standard has the potential of affecting the percentage of fetuses identified as SGA or LGA.

Birth weight standards before term are often not fully representative of normality, because a great proportion of preterm newborns are also growth restricted, and the prenatal diagnosis was missed. A major area of debate is whether a single universal growth reference chart should be used, or whether parental, ethnic and regional differences in fetal growth are best represented by customizing growth curves to individual characteristics.

“Intergrowth 21” is the name of a research project based at the University of Oxford, which produced a single and universally applicable growth standard, derived from a multi-ethnic population of eight countries.23 The underlying concept is that potential growth is similar in human beings, and that differences observed across countries and populations are mainly explained by variations in nutritional and health status.25 The standards therefore represent how all fetuses should grow under optimal conditions. To construct the reference curves, all pregnancy complications, congenital anomalies and stillbirths were excluded, and a novel formula was used to calculate EFW, based only on head circumference and abdominal circumference. Measurements were not revealed to the ultrasound operator, with the objective of avoiding corrections if extreme values were detected.24

Similar assumptions were taken to construct the WHO fetal growth standards, including data collected from ten countries.25 However, EFW was calculated using Hadlock’s 1985 formula.26 Due to the methodological differences in these studies, their 10th and 90th centiles vary substantially. For instance, at 28, 32 and 36 weeks, the 10th centile of Intergrowth 21 are 75, 164, and 208 g lower than those of the WHO, and the same tendency occurs with the 90th centile. Curiously, the WHO study concluded that maternal characteristics such as height, weight and parity contribute to the differences in growth patterns observed between countries.

A different approach is proposed by Gardosi et al.,27 known as customized Gestation-Related Optimal Weight (GROW) charts (, Birmingham, United Kingdom). These charts take into account maternal weight, height, ethnicity and parity, as well as fetal sex. Online software is used to calculate gestational age-related EFW curves that are individually customized.28,29 The model has been applied to several different datasets, allowing adaptations to the ethnic and nutritional characteristics of more than 25 countries.

A common criticism of customized growth charts is that nutritional status varies inside a country, namely between rural and urban areas, and that societies evolve due to changes in lifestyle and environment, as well as migratory fluxes. Anthropometric characteristics of the population will therefore evolve over time. The need to update reference ranges at regular intervals has been defended,30,31 but some argue that it is not feasible. A major argument in favor of customized growth curves is that it allows the identification of SGA fetuses in obese mothers that were previously unrecognized when using population-based curves. It also avoids the exaggerated detection of SGA fetuses in thin and nulliparous women, thus avoiding unnecessary investigations and interventions.32,33

Use of customized growth charts is recommended by some scientific societies,34 but a recent systematic review failed to show benefit over population-based charts in identification of SGA neonates at risk for adverse outcomes.35 Indeed it is difficult to show that growth curves improve the identification of pregnancies at increased risk of neonatal morbidity and mortality36,37,38 or adverse neurodevelopmental outcome.39

Currently, two approaches seem reasonable for ultrasound identification of SGA and LGA fetuses: use of customized growth curves adapted to the local population; use of population-based growth curves where the distribution of local population characteristics has been identified. For the latter, it is essential to understand that the definition of LGA and SGA fetuses may not coincide with the 10th and 90th centiles.


A single measurement of EFW can only indicate current size. Longitudinal evaluation is necessary to evaluate fetal growth, and to define a growth trajectory. Detection of an abnormal growth trajectory seems intuitively to be a better evaluator of a fetus failing to achieve its growth potential, the concept behind the definition of FGR. Both population-based and customized growth curves have been assumed to represent expected trajectories of normally growing fetuses.40,41 Customization based on the initial EFWs has also been proposed,42 generating trajectories that represent individualized boundaries for a normally growing fetus.43 Fetal growth velocity can be evaluated by changes in EFW or in specific biometric indexes (abdominal circumference or biparietal diameter).44,45 The earlier the first examination is performed, the less likely it is to be biased by factors that impair fetal growth.46

Evidence has suggested that abnormal abdominal circumference growth velocity is associated with perinatal morbidity, in both SGA and LGA fetuses.40,47 In SGA fetuses, those with abdominal circumference growth velocity in the lowest decile were at increased risk for neonatal morbidity (risk ratio [RR] 3.9; 95% confidence interval [CI] 1.9–8.1) compared with those showing normal abdominal circumference growth velocity.48 Similarly, LGA fetuses with increased abdominal circumference growth velocity had a higher risk of neonatal morbidity (RR, 2.0; 95% CI, 1.1–3.6).40

A potential limitation of the growth velocity approach is the statistical phenomenon called regression to the mean, which implies that any variable with an extreme value in its first measurement will tend to be closer to the mean when evaluated repeatedly. Curiously, in low-risk pregnancies, longitudinal assessment of fetal growth during the second and third trimesters has a lower predictive capacity for identifying SGA and late FGR than cross-sectional growth evaluation.49 In contrast, for high-risk pregnancies, a better prediction of adverse perinatal outcomes was achieved with serial ultrasound measurements.50,51 Because of these conflicting results52 and issues related to the cost of this approach, there is insufficient evidence to recommend its wide clinical use, and one-time measurements remain standard practice.

Further studies are required to optimize the performance of serial measurement strategies, particularly to determine the optimal timing and interval between exams.


Analysis of fetal body proportions is used to classify fetal growth as symmetric or asymmetric, in an attempt to distinguish between the different causes of FGR. When there is placental insufficiency, the brain-sparing effect causes abdominal circumference to be the first biometric index affected by nutritional deficiency. Fetal body proportion models use ratios between abdominal circumference and biometric indexes that are less affected by placental insufficiency, such as head circumference or femur length. The concepts of symmetric and asymmetric fetal growth were widely disseminated in past decades, namely as an aid to determine the etiology of FGR, but similarly to serial measurement strategies, there are conflicting results regarding their capacity to predict adverse perinatal outcomes.53,54


The biometric definition of SGA includes two different groups of fetuses: one that is in fact not achieving its genetic growth potential (true FGR) and another that is constitutionally small when compared with the reference population. Recent data suggest that additional ultrasound parameters help to distinguish these two groups and to guide subsequent management. Decreasing the cut-off value of EFW to <3rd centile reduces the number of constitutionally SGA fetuses and selects a higher-risk population, associated with the worst neonatal outcomes.55 Furthermore, the inclusion of functional data from umbilical, uterine, and middle cerebral artery Doppler flowmetry contributes to the identification of true FGR fetuses.56,57,58

Umbilical artery Doppler primarily reflects early-onset placental insufficiency, and most experts agree that EFW <10th centile and abnormal umbilical artery Doppler provide the best criteria to identify early-onset FGR (diagnosis before 32 weeks).59 However, umbilical artery Doppler does not reliably reflect placental insufficiency or predict adverse outcome in FGR detected beyond 32 weeks.60 Middle cerebral artery Doppler seems to be more valuable in the identification of late-onset FGR, as it has a stronger association with adverse perinatal and neurological outcomes.61

Cerebroplacental ratio, combining middle cerebral artery and umbilical artery pulsatility indexes, is an independent predictor of perinatal mortality, and seems to be more sensitive in detection of hypoxia than its individual components. Studies have shown that even in appropriately grown fetuses, an abnormal cerebroplacental ratio is associated with a higher incidence of adverse perinatal outcomes.62 The rationale behind this may be that these fetuses have a higher genetic growth potential and abnormal cerebroplacental ratio reflects a deceleration in fetal growth.

Uterine artery flowmetry reflects adequate trophoblastic invasion, an important step to guarantee adequate nutrient supply and gas exchange for the fetus. Although there is a positive association between abnormal uterine artery flow patterns and adverse outcomes such as pre-eclampsia and FGR, the predictive value of an isolated abnormal test is low, especially for late-onset FGR.59,63,64,65

Venous Doppler velocimetry does not have a role in the diagnosis of fetal growth anomalies, since changes appear late in the evolution of the disease. However, these measurements are useful for serial monitoring of fetal circulation, particularly in severe early-onset FGR.66,67

Oligohydramnios is frequently seen in FGR, following redistribution of blood flow to vital organs at the expense of others, such as the kidney. This parameter can be evaluated by measuring the amniotic fluid index or the single deepest vertical pocket. A randomized controlled trial comparing both methodologies found that amniotic fluid index was associated with more frequent diagnoses of oligohydramnios and increased rates of labor induction, without improving perinatal outcomes. Single deepest vertical pocket may therefore be more valuable, particularly in the low-risk population.68,69 Nonetheless, there is limited evidence to support its use in screening of FGR, or as a predictor of adverse outcome. Polyhydramnios is strongly associated with the diagnosis of LGA.70

A sequential approach to identify and manage FGR is widely used in high-resource settings,71 where EFW is followed by Doppler evaluations to help differentiate between constitutional SGAs and pathological fetal growth anomalies, and also to guide management and timing of interventions.


  • Ultrasound remains the mainstay of diagnosis in fetal growth anomalies.
  • Estimated fetal weight is the most widely used parameter to detect abnormal growth.
  • There is currently no consensus on which fetal growth charts should be used to predict adverse outcome associated with abnormal fetal growth
  • To detect small- and large-for-gestational age fetuses, customized growth curves adapted to the local population may be used, or population-based growth curves where the distribution of local population characteristics has been identified, and may not coincide with the 10th and 90th centiles.
  • There are insufficient data to recommend the routine use of serial fetal growth evaluations as predictors of adverse perinatal outcomes
  • Doppler parameters (umbilical artery, uterine artery, middle cerebral artery and cerebroplacental index) help to distinguish between SGA and true FGR, and guide management and timing of interventions.


The author(s) of this chapter declare that they have no interests that conflict with the contents of the chapter.



Mayer C, Joseph KS. Fetal growth: a review of terms, concepts and issues relevant to obstetrics. Ultrasound Obstet Gynecol 2013;41(2):136–45.


Fretts RC, Boyd ME, Usher RH, Usher HA. The changing pattern of fetal death, 1961–1988. Obstet Gynecol 1992;79(1):35–9.


Lawn JE, Blencowe H, Waiswa P, Amouzou A, Mathers C, Hogan D, et al. Stillbirths: rates, risk factors, and acceleration towards 2030. Lancet 2016;387(10018):587–603.


Lindqvist PG, Molin J. Does antenatal identification of small-for-gestation age fetuses significantly improve their outcome? Ultrasound Obstet Gynecol 2005;25:258–64.


Gardosi J, Madurasinghe V, Williams M, Malik A, Francis A. Maternal and fetal risk factors for stillbirth: population based study. BMJ 2013;346:f108.


Ju H, Chadha Y, Donovan T, O'Rourke P. Fetal macrosomia and pregnancy outcomes. Aust N Z J Obstet Gynaecol 2009;49:504–9.


King JR, Korst LM, Miller DA, Ouzounian JG. Increased composite maternal and neonatal morbidity associated with ultrasonographically suspected fetal macrosomia. J Matern Fetal Neonatal Med 2012;25:1953–9.


Sparks TN, Cheng YW, McLaughlin B, Esakoff TF, Caughey AB. Fundal height: a useful screening tool for fetal growth? J Matern Fetal Neonatal Med 2011;24(5):708–12.


Morse K, Williams A, Gardosi J. Fetal growth screening by fundal height measurement. Best Pract Res Clin Obstet Gynaecol 2009;23(6):809–18.


Chauhan SP, Grobman WA, Gherman RA, Chauhan VB, Chang G, Magann EF, et al. Suspicion and treatment of the macrosomic fetus: a review. Am J Obstet Gynecol 2005;193(2):332–46.


Bricker L, Medley N, Pratt JJ. Routine ultrasound in late pregnancy (after 24 weeks' gestation). Cochrane Database Syst Rev 2015;6:CD001451.


World Health Organization. WHO recommendations on antenatal care for a positive pregnancy experience. Geneva, 2016


American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 134: fetal growth restriction. Obstet Gynecol 2013;121:1122–33.


Miettinen OS. Theoretical epidemiology: principles of occurrence research in medicine. Toronto: John Wiley & Sons, 1985.


Joseph KS, Fahey TJ, Platt RW, Liston RM, Lee SK, Sauve R, et al. An outcome-based approach for the creation of fetal growth standards: do singletons and twins need separate standards? Am J Epidemiol 2009;169:616–624.


Bovicelli L, Orsini LF, Rizzo N, Calderoni P, Pazzaglia FL, Michelacci L. Estimation of gestational age during the first trimester by real-time measurement of fetal crown-rump length and biparietal diameter. J Clin Ultrasound 1981;9:71–5.


Selbing A. Gestational age and ultrasonic measurement of gestational sac, crown-rump length and biparietal diameter during first 15 weeks of pregnancy. Acta Obstet Gynecol Scand 1982;61:233–5.


Papageorghiou AT, Kennedy SH, Salomon LJ, Ohuma EO, Cheikh Ismail L, Barros FC, et al. International standards for early fetal size and pregnancy dating based on ultrasound measurement of crown-rump length in the first trimester of pregnancy. Ultrasound Obstet Gynecol 2014;44(6):641–8.


Warsof SL, Cooper DJ, Little D, Campbell S. Routine ultrasound screening for antenatal detection of intrauterine growth retardation. Obstet Gynecol 1986;67(1):33–9.


Chang TC, Robson SC, Boys RJ, Spencer JA. Prediction of the small for gestational age infant: which ultrasonic measurement is best? Obstet Gynecol 1992;80(6):1030–8.


Chambers SE, Hoskins PR, Haddad NG, Johnstone FD, McDicken WN, Muir BB. A comparison of fetal abdominal circumference measurements and Doppler ultrasound in the prediction of small-for-dates babies and fetal compromise. Br J Obstet Gynaecol 1989;96(7):803–8.


Pedersen NG, Figueras F, Wøjdemann KR, Tabor A, Gardosi J. Early fetal size and growth as predictors of adverse outcome. Obstet Gynecol 2008;112(4):765–71.


Stirnemann J, Villar J, Salomon LJ, Ohuma E, Ruyan P, Altman DG, et al. International estimated fetal weight standards of the INTERGROWTH-21st Project. Ultrasound Obstet Gynecol 2017;49(4):478–486.


Kiserud T, Benachi A, Hecher K, Perez RG, Carvalho J, Piaggio G, et al. The World Health Organization fetal growth charts: concept, findings, interpretation, and application. Am J Obstet Gynecol 2018;218(2S):S619-S629.


Kiserud T, Piaggio G, Carroli G, Widmer M, Carvalho J, Neerup Jensen L, et al. The World Health Organization Fetal Growth Charts: A multinational longitudinal study of ultrasound biometric measurements and estimated fetal weight. PLoS Med 2017;14(1):e1002220.


Hadlock FP, Harrist RB, Sharman RS, Deter RL, Park SK. Estimation of fetal weight with the use of head, body, and femur measurements–a prospective study. Am J Obstet Gynecol 1985;151(3):333–7.


Gardosi J, Francis A, Turner S, Williams M. Customized growth charts: rationale, validation and clinical benefits. Am J Obstet Gynecol 2018;218:S609–18.


Gardosi J, Mongelli M, Wilcox M, Chang A. An adjustable fetal weight standard. Ultrasound Obstet Gynecol 1995;6(3):168–74.


Hadlock FP, Harrist RB, Martinez-Poyer J. In utero analysis of fetal growth: a sonographic weight standard. Radiology 1991;181(1):129–33.


Mikolajczyk RT, Zhang J, Betran AP, Souza JP, Mori R, Gülmezoglu AM, et al. A global reference for fetal-weight and birthweight percentiles. Lancet 2011;377(9780):1855–61.


Figueras F, Meler E, Iraola A, Eixarch E, Coll O, Figueras J, et al. Customized birthweight standards for a Spanish population. Eur J Obstet Gynecol Reprod Biol 2008;136(1):20–4.


Gardosi J, Clausson B, Francis A. The value of customised centiles in assessing perinatal mortality risk associated with parity and maternal size. BJOG 2009;116(10):1356–63.


Gardosi J, Francis A. Adverse pregnancy outcome and association with small for gestational age birthweight by customized and population-based percentiles. Am J Obstet Gynecol 2009;201(1):28.e1–8.


Royal College of Obstetricians and Gynaecologists. The investigation and management of the small for gestational age fetus. Green Top Guideline No 31. London, UK: RCOG, 2013.


Chiossi G, Pedroza C, Costantine MM, Truong VTT, Gargano G, Saade GR. Customized vs. population-based growth charts to identify neonates at risk of adverse outcome: systematic review and Bayesian meta-analysis of observational studies. Ultrasound Obstet Gynecol 2017;50(2):156–66.


Groom KM, Poppe KK, North RA, McCowan LM. Small-for-gestational-age infants classified by customized or population birthweight centiles: impact of gestational age at delivery. Am J Obstet Gynecol 2007;197(3):239.e1–5.


Zhang X, Platt RW, Cnattingius S, Joseph KS, Kramer MS. The use of customised versus population-based birthweight standards in predicting perinatal mortality. BJOG 2007;114(4):474–7.


Larkin JC, Hill LM, Speer PD, Simhan HN. Risk of morbid perinatal outcomes in small-for-gestational-age pregnancies: customized compared with conventional standards of fetal growth. Obstet Gynecol 2012;119(1):21–7.


Neta G, Grewal J, Mikolajczyk R, Klebanoff M, Zhang J. Does the individualized reference outperform a simple ultrasound-based reference applied to birth weight in predicting child neurodevelopment? Ultrasound Obstet Gynecol 2011;38(1):62–6.


Sovio U, Moraitis AA, Wong HS, Smith GCS. Universal vs. selective ultrasonography to screen for large-for-gestational-age infants and associated morbidity. Ultrasound Obstet Gynecol 2018;51(6):783–91.


Deter RL, Lee W, Sangi-Haghpeykar H, Tarca AL, Li J, Yeo L, et al. Personalized third-trimester fetal growth evaluation: comparisons of individualized growth assessment, percentile line and conditional probability methods. J Matern Fetal Neonatal Med 2016;29(2):177–85.


Owen P, Ogston S. Conditional centiles for the quantification of fetal growth. Ultrasound Obstet Gynecol 1998;11(2):110–7.


Deter RL, Lee W, Sangi-Haghpeykar H, Tarca AL, Yeo L, Romero R. Individualized fetal growth assessment: critical evaluation of key concepts in the specification of third trimester size trajectories. J Matern Fetal Neonatal Med 2014;27(6):543–51.


Mongelli M, Benzie R, Condous G. Average fetal weekly weight gain: a novel measure of fetal growth velocity. J Matern Fetal Neonatal Med 2016;29(4):676–9.


Vannuccini S, Ioannou C, Cavallaro A, Volpe G, Ruiz-Martinez S, Impey L. A reference range of fetal abdominal circumference growth velocity between 20 and 36 weeks' gestation. Prenat Diagn 2017;37(11):1084–1092.


Deter RL, Lee W, Yeo L, Erez O, Ramamurthy U, Naik M, et al. Individualized growth assessment: conceptual framework and practical implementation for the evaluation of fetal growth and neonatal growth outcome. Am J Obstet Gynecol 2018;218(2S):S656-S78.


Romero R, Deter R. Should serial fetal biometry be used in all pregnancies? Lancet 2015;386(10008):2038–40.


Sovio U, White IR, Dacey A, Pasupathy D, Smith GCS. Screening for fetal growth restriction with universal third trimester ultrasonography in nulliparous women in the Pregnancy Outcome Prediction (POP) study: a prospective cohort study. Lancet 2015;386(10008):2089–97.


Caradeux J, Eixarch E, Mazarico E, Basuki TR, Gratacós E, Figueras F. Second- to third-trimester longitudinal growth assessment for prediction of small-for-gestational age and late fetal growth restriction. Ultrasound Obstet Gynecol 2018;51(2):219–224.


Karlsen HO, Johnsen SL, Rasmussen S, Kiserud T. Prediction of adverse perinatal outcome of small-for-gestational-age pregnancy using size centiles and conditional growth centiles. Ultrasound Obstet Gynecol 2016;48(2):217–23.


de Jong CL, Francis A, van Geijn HP, Gardosi J. Fetal growth rate and adverse perinatal events. Ultrasound Obstet Gynecol 1999;13(2):86–9.


Iraola A, González I, Eixarch E, Meler E, Illa M, Gardosi J, et al. Prediction of adverse perinatal outcome at term in small-for-gestational age fetuses: comparison of growth velocity vs. customized assessment. J Perinat Med 2008;36(6):531–5.


Colley NV, Tremble JM, Henson GL, Cole TJ. Head circumference/abdominal circumference ratio, ponderal index and fetal malnutrition. Should head circumference/abdominal circumference ratio be abandoned? Br J Obstet Gynaecol 1991;98(6):524–7.


Lin CC, Su SJ, River LP. Comparison of associated high-risk factors and perinatal outcome between symmetric and asymmetric fetal intrauterine growth retardation. Am J Obstet Gynecol 1991;164(6 Pt 1):1535–42.


Unterscheider J, Daly S, Geary MP, Kennelly MM, McAuliffe FM, O'Donoghue K, et al. Optimizing the definition of intrauterine growth restriction: the multicenter prospective PORTO Study. Am J Obstet Gynecol 2013;208:290.e1–6.


O'Dwyer V, Burke G, Unterscheider J, Daly S, Geary MP, Kennelly MM, et al. Defining the residual risk of adverse perinatal outcome in growth-restricted fetuses with normal umbilical artery blood flow. Am J Obstet Gynecol 2014;211:420.e1–5


Stampalija T, Casati D, Monasta L, Sassi R, Rivolta MW, Muggiasca ML, et al. Brain sparing effect in growth-restricted fetuses is associated with decreased cardiac acceleration and deceleration capacities: a case-control study. BJOG 2016;123:1947–1954.


Poljak B, Agarwal U, Jackson R, Alfirevic Z, Sharp A. Diagnostic accuracy of individual antenatal tools for the detection of the small for gestational age newborn. Ultrasound Obstet Gynecol 2017;49(4):493–499.


Gordijn SJ, Beune IM, Thilaganathan B, Papageorghiou A, Baschat AA, Baker PN, et al. Consensus definition of fetal growth restriction: a Delphi procedure. Ultrasound Obstet Gynecol 2016;48(3):333–9.


Oros D, Figueras F, Cruz-Martinez R, Meler E, Munmany M, Gratacos E. Longitudinal changes in uterine, umbilical and fetal cerebral Doppler indices in late-onset small-for-gestational age fetuses. Ultrasound Obstet Gynecol 2011;37:191–5.


Severi FM, Bocchi C, Visentin A, Falco P, Cobellis L, Florio P, et al. Uterine and fetal cerebral Doppler predict the outcome of third-trimester small-for-gestational age fetuses with normal umbilical artery Doppler. Ultrasound Obstet Gynecol 2002;19:225–8


Khalil A, Morales-Roselló J, Townsend R, Morlando M, Papageorghiou A, Bhide A, et al. Value of third-trimester cerebroplacental ratio and uterine artery Doppler indices as predictors of stillbirth and perinatal loss. Ultrasound Obstet Gynecol 2016;47:74–80.


Chien PF, Arnott N, Gordon A, Owen P, Khan KS. How useful is uterine artery Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth retardation and perinatal death? An overview. BJOG 2000;107(2):196–208.


Velauthar L, Plana MN, Kalidindi M, Zamora J, Thilaganathan B, Illanes SE, et al. First-trimester uterine artery Doppler and adverse pregnancy outcome: a meta-analysis involving 55,974 women. Ultrasound Obstet Gynecol 2014;43(5):500–7.


Cruz-Martinez R, Savchev S, Cruz-Lemini M, Mendez A, Gratacos E, Figueras F. Clinical utility of third-trimester uterine artery Doppler in the prediction of brain hemodynamic deterioration and adverse perinatal outcome in small-for-gestational-age fetuses. Ultrasound Obstet Gynecol 2015;45(3):273–8.


Baschat AA, Gembruch U, Harman CR. The sequence of changes in Doppler and biophysical parameters as severe fetal growth restriction worsens. Ultrasound Obstet Gynecol 2001;18:571–7.


Baschat AA, Galan HL, Bhide A, Berg C, Kush ML, Oepkes D, et al. Doppler and biophysical assessment in growth restricted fetuses: distribution of test results. Ultrasound Obstet Gynecol 2006;27(1):41–7.


Kehl S, Schelkle A, Thomas A, Puhl A, Meqdad K, Tuschy B, et al. Single deepest vertical pocket or amniotic fluid index as evaluation test for predicting adverse pregnancy outcome (SAFE trial): a multicenter, open-label, randomized controlled trial. Ultrasound Obstet Gynecol 2016;47(6):674–9.


Nabhan AF, Abdelmoula YA. Amniotic fluid index versus single deepest vertical pocket as a screening test for preventing adverse pregnancy outcome. Cochrane Database Syst Rev 2008;(3):CD006593.


Morris RK, Meller CH, Tamblyn J, Malin GM, Riley RD, Kilby MD, et al. Association and prediction of amniotic fluid measurements for adverse pregnancy outcome: systematic review and meta-analysis. BJOG 2014;121(6):686–99.


Figueras F, Gratacos E. An integrated approach to fetal growth restriction. Best Pract Res Clin Obstet Gynaecol 2017;38:48–58.

Online Study Assessment Option
All readers who are qualified doctors or allied medical professionals can now automatically receive 2 Continuing Professional Development credits from FIGO plus a Study Completion Certificate from GLOWM for successfully answering 4 multiple choice questions (randomly selected) based on the study of this chapter.
Medical students can receive the Study Completion Certificate only.


(To find out more about FIGO’s Continuing Professional Development awards programme CLICK HERE)